• Glypican-3 expression in Wilms tumor and hepatoblastoma.

• Brain metastases in Wilms' tumor: case report and literature review.

• Brief report: biliary emesis as the presenting sign in a neonate with Wilms tumor.

• Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group.

• Combined endoscopic resection and brachytherapy for recurrent intrapelvic Wilms tumor.

1
UI - 11878776
AU - Toretsky JA; Zitomersky NL; Eskenazi AE; Voigt RW; Strauch ED; Sun CC;
TI - Huber R; Meltzer SJ; Schlessinger D Glypican-3 expression in Wilms tumor and hepatoblastoma.
SO - J Pediatr Hematol Oncol 2001 Nov;23(8):496-9
AD - Department of Pediatrics, and Greenebaum Cancer Center, University of Maryland School of Medicine and Baltimore VA Medical Center, USA.
BACKGROUND: Glypican-3 (GPC3) is a heparan sulfate proteoglycan. When it is disrupted, it causes the X-linked gigantism-overgrowth Simpson-Golabi-Behmel syndrome. Its involvement in growth control is consistent with recent reports that it can bind to growth factors, possibly including insulin-like growth factor 2. Further, it has been hypothesized that it may function as a tumor suppressor gene in breast and ovarian carcinomas and mesotheliomas. PATIENTS AND METHODS: RNA and protein were extracted from Wilms tumor and hepatoblastoma tissue samples and GPC3 levels were measured in these extracts by Northern blotting, reverse transcription polymerase chain reaction, and immunoblotting. RESULTS: In contrast to published results with carcinomas, high levels of GPC3 expression were found in Wilms tumor and hepatoblastoma. Low or undetectable expressions of this gene were found in normal tissue surrounding the tumor. CONCLUSIONS: Increased expression of GPC3 in Wilms tumor and hepatoblastoma suggests a growth-promoting or neutral activity for this gene product rather than a growth-suppressive effect.

2
UI - 11990704
AU - MacRae R; Grimard L; Hsu E; Nizalik E; Halton JM
TI - Brain metastases in Wilms' tumor: case report and literature review.
SO - J Pediatr Hematol Oncol 2002 Feb;24(2):149-53
AD - Ottawa Regional Cancer Center and the Children's Hospital of Eastern Ontario, Canada.
A 2-year-old girl who had a stage 2, favorable-histology Wilms tumor diagnosed when she was age 10 months presented with multiple brain metastases at second recurrence. She had been treated with combined radiotherapy, surgery, and chemotherapy; at 2 months after treatment, recurrent disease developed in the central nervous system and she died. Brain metastases are rare in the natural history of Wilms tumor. Although it does not appear that cerebral metastases are a barrier to tumor eradication and long-term survival if treated with combined modality therapy, treatment should be individualized.

3
UI - 11979467
AU - Parigi GB; Magni M; Cassani F; Puletti G; Bragheri R
TI - Brief report: biliary emesis as the presenting sign in a neonate with Wilms tumor.
SO - Med Pediatr Oncol 2002 May;38(5):374-5
AD - Department of Pediatric Surgery, Universita degli Studi, Pavia, Italy. gbparigi@smatteo.pv.it

4
UI - 12011129
AU - Green DM; Peabody EM; Nan B; Peterson S; Kalapurakal JA; Breslow NE
TI - Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group.
SO - J Clin Oncol 2002 May 15;20(10):2506-13
AD - Department of Pediatrics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. daniel.green@roswellpark.org
PURPOSE: This study was undertaken to determine the effect, if any, of prior treatment with radiation therapy or chemotherapy for Wilms tumor diagnosed during childhood or adolescence on live births, birthweight, and the frequency of congenital malformations. PATIENTS AND METHODS: We reviewed pregnancy outcomes among survivors of Wilms tumor treated with or without irradiation to the flank or tumor bed on National Wilms Tumor Studies 1, 2, 3, and 4 using a maternal questionnaire and review of both maternal and offspring medical records. RESULTS: We received reports regarding 427 pregnancies with duration of 20 weeks or longer, including 409 liveborn singletons for whom 309 sets of medical records were reviewed. Malposition of the fetus and early or threatened labor were more frequent among irradiated women. Both were more frequent among women who received higher radiation therapy doses. The offspring of the irradiated female patients were more likely to weigh less than 2,500 g at birth and to be of less than 36 weeks gestation, with both being more frequent after higher doses of radiation. An increased percentage of offspring of irradiated females had one or more congenital malformations. CONCLUSION: Women who receive flank radiation therapy as part of their treatment for Wilms tumor are at increased risk of fetal malposition and premature labor. The offspring of these women are at risk for low birthweight, premature (< 36 weeks gestation) birth, and the occurrence of congenital malformations. These risks must be considered in the obstetrical management of female survivors of Wilms tumor.

5
UI - 11992083
AU - McManus MC; Silliman C; Koyle MA
TI - Combined endoscopic resection and brachytherapy for recurrent intrapelvic Wilms tumor.
SO - J Urol 2002 Jun;167(6):2540
AD - Department of Pediatric Urology, The Children's Hospital, University of Colorado School of Medicine, Denver, CO, USA.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

About OncoLink  Contact OncoLink  Privacy statement   Disclaimer  Link to OncoLink  Home
For assistance please visit our HELP section
© Trustees of the University of Pennsylvania